An observational study in Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC) and IBD-unclassified (IBD-U), sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 14 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Massachusetts General Hospital · Observational
Among 13 studies in Inflammatory Bowel Diseases by Massachusetts General Hospital — 7 open to participants now, 8 under way, none of them phase 3. Inflammatory Bowel Diseases · Massachusetts General Hospital.
Among the 13 studies in Inflammatory Bowel Diseases by Massachusetts General Hospital, this one is the only one that started in 2024, is one of 3 observational ones, and was the 9th registered.
1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 426 are open to participants now.
Browse Inflammatory Bowel Diseases studies →7 of the 13 studies in Inflammatory Bowel Diseases by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Massachusetts General Hospital · Sites in United States
Massachusetts General Hospital · Sites in United States
Massachusetts General Hospital · Sites in United States
Massachusetts General Hospital · Sites in United States
By country, each count listing its studies:
Of the 278 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 118 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.
This study: 14 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 50 is below the median of 140 across 626 observational studies indexed under Inflammatory Bowel Diseases.
Median enrollment 40 across the 10 interventional studies, 50 across the 3 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,586 studies on the registry; 447 are open to participants now.
Of its 222 completed or terminated interventional studies of FDA-regulated products, 168 (76%) have results posted.
5 of the studies in Inflammatory Bowel Diseases by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04508088Massachusetts General HospitalSkeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease | 2026-12 |
| NCT04565821Massachusetts General HospitalFeasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe | 2027-04-30 |
| NCT07033208Massachusetts General HospitalFeasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance | 2027-04-30 |
| NCT07168499Massachusetts General HospitalDiet and Stress Management Combined With Advanced Therapy for Crohn's and Ulcerative Colitis | 2027-05-01 |
| NCT05332639Massachusetts General HospitalPersonalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility | 2027-11 |
Among the 13 studies in Inflammatory Bowel Diseases by Massachusetts General Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
First-degree relatives of people with inflammatory bowel disease ("IBD," including Crohn's disease and ulcerative colitis) have an increased risk for developing IBD themselves. This study will follow unaffected first-degree relatives (who do not have IBD) over time to understand if their behaviors, diet, and biomarkers for IBD can help predict who gets IBD and if IBD can be prevented in these high-risk individuals. Participants will be asked once per year to complete a questionnaire and have their blood, stool, and urine collected. The anticipated length of the study (registry) is approximately 10 years or longer. Parts of this study, such as the questionnaires and stool and urine collection, may be done from home, while other parts, such as the blood draw, will need to be done from Massachusetts General Hospital.
First-degree relatives (FDRs) of those with IBD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult and adolescent (greater than 14 years of age) first-degree relatives (parents, siblings, or children) of patients with inflammatory bowel disease (including Crohn's disease, ulcerative colitis, or inflammatory bowel disease-unclassified/indeterminate colitis) but who do not have inflammatory bowel disease themselves.
Number of participants who develop inflammatory bowel disease
Participants will be queried annually on questionnaires for the development of inflammatory bowel disease (IBD), including Crohn's disease, ulcerative colitis, or IBD-U (self-reported outcome). Participants will then be asked for permission to obtain additional medical records, which will be reviewed by study investigators to confirm diagnosis of IBD.
Time frame: Through study completion (an anticipated 10 years)
Plan to share: Yes — De-identified data may be available upon reasonable request and per Mass General Brigham IRB guidelines as outlined in the ICF and detailed protocol.
Access criteria: Collaborators interested in requesting data must submit a valid scientific question, include a statistical analysis plan, complete a data request form, and Data Use Agreement (DUA), which limits subsequent use to the terms of the approved request and requires that users maintain data security, and refrain from any attempts to re-identify research participants or engage in any unauthorized uses of the data.
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2034, 120 months after the start.
Of 243 non-industry observational studies under Inflammatory Bowel Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 132. This study's planned 120 months is above that.
Counting every sponsor, half of 280 studies reached it within 36 months; a quarter within 20 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →